Medicure Reports Q2 2025 Financial Results

Medicure Inc., a pharmaceutical company in the U.S. market, has released its financial results for the quarter ending June 30, 2025. The company reported a total net revenue of $6.7 million, up from $5.2 million the previous year. Revenue from AGGRASTAT® sales remained stable, while the Marley Drug business showed an increase to $3.1 million, partly due to higher ZYPITAMAG® sales.

Despite these increases, Medicure recorded an overall net loss of $786,000, a notable improvement from the $1.2 million loss in the same quarter last year. Adjusted EBITDA improved, showing a negative $28,000 compared to negative $514,000 year-on-year. The company's research and development spending underscored its commitment to innovation, with a focus on the Phase 3 trial of MC-1 for PNPO deficiency.

Medicure's liquidity situation changed, with unrestricted cash decreasing to $4.7 million from $7.2 million recorded at the end of 2024, primarily due to acquisitions.